Icatibant Acetate丨CAS 138614-30-9

Icatibant acetate is a synthetic peptide used primarily in pharmaceutical and biomedical research as a selective bradykinin B2 receptor antagonist. Clinically, it is applied for the treatment of hereditary angioedema (HAE) to rapidly reduce acute episodes of swelling by blocking bradykinin-mediated vascular permeability. In research settings, it is used to study the bradykinin signaling pathway, vascular biology, inflammation, and the role of B2 receptors in cardiovascular and inflammatory conditions. The compound is also employed as a reference in preclinical and pharmacological studies to evaluate the efficacy, pharmacokinetics, and receptor binding of new peptide or small-molecule B2 receptor antagonists. Its water-soluble acetate form allows for convenient preparation in experimental and clinical formulations.

Icatibant acetate offers several advantages that make it valuable in therapeutic and research applications. Its high specificity for bradykinin B2 receptors ensures targeted action, minimizing off-target effects and improving safety profiles in clinical use. The peptide's rapid onset of action provides quick relief in acute HAE attacks, demonstrating effective receptor blockade in vivo. Its stability as an acetate salt enhances solubility and facilitates formulation for injection or laboratory assays. In research, Icatibant acetate serves as a reliable tool to explore bradykinin-related pathways, receptor interactions, and inflammatory mechanisms, supporting drug discovery and mechanistic studies. Its well-characterized pharmacological profile allows consistent and reproducible results across studies.